ChiCTR2200056699 版本V1.0 版本创建时间2023/01/20 16:33:01 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2200056699 

最近更新日期:

Date of Last Refreshed on:

2022-02-10 07:09:13 

注册时间:

Date of Registration:

2022-02-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于多学科团队决策干预的老年尿失禁管理的前瞻性多中心随机对照研究

Public title:

Management of urinary incontinence based on multidisciplinary team decision-making in Chinese older adults(CO-MUI study): a prospective, multicenter, randomized, controlled study

注册题目简写:

CO-MUI

English Acronym:

研究课题的正式科学名称:

基于多学科团队决策干预的老年尿失禁管理的前瞻性多中心随机对照研究

Scientific title:

Management of urinary incontinence based on multidisciplinary team decision-making in Chinese older adults(CO-MUI study): a prospective, multicenter, randomized, controlled study

研究课题代号(代码):

Study subject ID:

2020YFC2008604

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

宋雨 

研究负责人:

李耘 

Applicant:

Song Yu 

Study leader:

Li Yun 

申请注册联系人电话:

Applicant telephone:

13901217262

研究负责人电话:

Study leader's
telephone:

13601307723

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

sykyle@126.com

研究负责人电子邮件:

Study leader's E-mail:

liy_xw@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区长椿街45号首都医科大学宣武医院

研究负责人通讯地址:

北京市西城区长椿街45号首都医科大学宣武医院

Applicant address:

Xuanwu Hospital Capital Medical University, No.45 Changchun Street, Xicheng District, Beijing, China

Study leader's address:

Xuanwu Hospital Capital Medical University, No.45 Changchun Street, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100053

研究负责人邮政编码:

Study leader's postcode:

100053

申请人所在单位:

首都医科大学宣武医院

Applicant's institution:

Xuanwu Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学宣武医院

Affiliation of the Leader:

Xuanwu Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临研审[2021]060号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学宣武医院伦理委员会

Name of the ethic committee:

Ethics Committee of Xuanwu Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-04-12 00:00:00

伦理委员会联系人:

胡晓

Contact Name of the ethic committee:

Hu Xiao

伦理委员会联系地址:

北京市西城区长椿街45号首都医科大学宣武医院

Contact Address of the ethic committee:

Xuanwu Hospital Capital Medical University, No.45 Changchun Street, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学宣武医院

Primary sponsor:

Xuanwu Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市长椿街45号首都医科大学宣武医院

Primary sponsor's address:

Xuanwu Hospital Capital Medical University, No.45 Changchun Street, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院

具体地址:

北京市西城区长椿街45号

Institution
hospital:

Xuanwu Hospital, Capital Medical University

Address:

45 Changchun Street, Xicheng District, Beijing

经费或物资来源:

国家重点研发计划专项课题(项目编号:2020YFC2008604)

Source(s) of funding:

National Key R&D Program of China (Project No.: 2020YFC2008604)

研究疾病:

尿失禁  

Target disease:

urinary incontinence

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评价多学科团队决策干预管理的老年尿失禁患者,其尿失禁改善效果与现有普通干预措施干预管理的老年尿失禁患者有无区别。  

Objectives of Study:

To evaluate the difference in urinary incontinence improvement effect between elderly patients with urinary incontinence managed by multidisciplinary team decision-making intervention and existing common interventions.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1、患者年龄≥60周岁;
2、意识清楚,语言表达能力正常,能够有效沟通;
3、符合尿失禁诊断;
4、预计住院时间≥4天;
5、可随访1年以上;
6、签署知情同意书,自愿参与研究。

Inclusion criteria

1) Age ≥ 60 years;
2) patients with clear consciousness who can communicate with researchers effectively;
3) consistent with the diagnosis of urinary incontinence;
4) length of stay ≥ 4 days;
5) patients who can be followed up for >1 year;
6) patients who can sign informed consent voluntarily and cooperate with the smooth implementation of the research.

排除标准:

1、精神、意识障碍、重度认知功能障碍,无法进行有效沟通交流;
2、患者依从性差,无法配合完成评估与干预;
3、患者本人及家属拒绝参与本研究;
4、疾病终末期;急性心肌梗死;剥离性主动脉瘤;重度主动脉瓣狭窄;心内膜炎/急性心包膜炎;急性血栓栓塞症;近期大手术或过去1个月发生肢体骨折者;
5、存在研究者认为需排除的其他状况。

Exclusion criteria:

1) Mental and consciousness disorders, severe cognitive impairment, and inability to communicate effectively; 2) patient compliance is poor and patients cannot cooperate to complete the evaluation and intervention;
3) the patient himself or his family refused to participate in the study;
4) end-stage disease, acute myocardial infarction, dissecting aortic aneurysm, severe aortic stenosis, endocarditis/acute pericarditis, acute thromboembolism, recent major surgery, or limb fracture in the past 1 month;
5) any other conditions that the researchers believe should be excluded.

研究实施时间:

Study execute time:

From 2021-11-01 00:00:00 To 2024-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-02-28 00:00:00 To 2024-01-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

180

Group:

experimental group

Sample size:

干预措施:

根据循证指南进行集非手术及手术治疗为一体的多学科团队管理策略

干预措施代码:

Intervention:

Implement a multidisciplinary team management strategy integrating non-surgical and surgical treatment according to evidence-based guidelines

Intervention code:

组别:

对照组

样本量:

180

Group:

control group

Sample size:

干预措施:

常规治疗管理模式

干预措施代码:

Intervention:

Routine treatment management mode

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

中南大学湘雅医院 

单位级别:

三甲 

Institution
hospital:

Xiangya Hospital Central South University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院 

单位级别:

三甲 

Institution
hospital:

Xuanwu Hospital, Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

浙江 

市(区县):

杭州 

Country:

China

Province:

Zhejiang

City:

Hangzhou

单位(医院):

浙江医院 

单位级别:

三甲 

Institution
hospital:

Zhejiang Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China

Province:

Fujian

City:

Fuzhou

单位(医院):

福建医科大学附属协和医院 

单位级别:

三甲 

Institution
hospital:

Fujian Medical University Union Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

国际尿失禁咨询委员会尿失禁问卷简表分数

指标类型:

主要指标

Outcome:

score of ICI-Q-SF

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿常规

指标类型:

次要指标

Outcome:

routine urine test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

残余尿体积

指标类型:

次要指标

Outcome:

postvoid residual volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

尿流动力学

指标类型:

次要指标

Outcome:

urodynamics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日常生活活动能力评估量表

指标类型:

次要指标

Outcome:

ADL

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

谵妄量表

指标类型:

次要指标

Outcome:

CAM

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评量表

指标类型:

次要指标

Outcome:

SAS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

老年抑郁量表

指标类型:

次要指标

Outcome:

GDS-15

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

全因死亡

指标类型:

次要指标

Outcome:

all-cause death

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计师采用计算机软件产生随机序列,研究者可申请得到随机结果

Randomization Procedure (please state who generates the random number sequence and by what method):

Statisticians use computer software to generate random sequences. Researchers apply for random results from statisticians

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

开放标签

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

待课题结束,数据全部完成后共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

the data will be shared after the end of the project

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有数据采用CRF记录,数据录入采用Epidata

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All the data will be recorded in CRF and Epidata is used for data entry

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-02-10 07:09:13